Mercury Biopharmaceutical Corporation (TPEX:6932)
Taiwan · Delayed Price · Currency is TWD 8.68
-0.36 (-3.98%)
Aug 12, 2025, 1:57 PM CST
Model N Revenue
In the year 2024, Mercury Biopharmaceutical had annual revenue of 4.96M TWD with 380.45% growth. Mercury Biopharmaceutical had revenue of 246.00K in the half year ending December 31, 2024, a decrease of -90.82%.
Revenue
4.96M
Revenue Growth
+380.45%
P/S Ratio
768.38
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.96M | 3.93M | 380.45% |
| Dec 31, 2023 | 1.03M | -1.65M | -61.46% |
| Dec 31, 2022 | 2.68M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caliway Biopharmaceuticals | 40.47M |
| PharmaEssentia | 11.34B |
| Bora Pharmaceuticals Co., LTD. | 21.32B |
| Lotus Pharmaceutical | 19.12B |
| Oneness Biotech | 112.57M |
| Polaris Group | 87.67M |
| Center Laboratories | 1.63B |
| Pegavision | 6.67B |